Page last updated: 2024-10-22

dan 2163 and Depression, Involutional

dan 2163 has been researched along with Depression, Involutional in 10 studies

Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.

Research Excerpts

ExcerptRelevanceReference
" Secondary outcomes included psychopathology, remission, all-cause-discontinuation, inefficacy-related discontinuation, and adverse events."3.01Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. ( Correll, CU; Hagi, K; Kane, JM; Kishimoto, T; Kurokawa, S, 2023)
" However, no correlation between prolactin levels and dosage could be found."1.32[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics]. ( Fric, M; Laux, G, 2003)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (20.00)29.6817
2010's5 (50.00)24.3611
2020's3 (30.00)2.80

Authors

AuthorsStudies
Kishimoto, T1
Hagi, K1
Kurokawa, S1
Kane, JM1
Correll, CU1
Carstens, L1
Popp, M1
Keicher, C1
Hertrampf, R1
Weigner, D1
Meiering, MS1
Luippold, G1
Süssmuth, SD1
Beckmann, CF1
Wunder, A1
Grimm, S1
Liu, Y1
Admon, R1
Mellem, MS1
Belleau, EL1
Kaiser, RH1
Clegg, R1
Beltzer, M1
Goer, F1
Vitaliano, G1
Ahammad, P1
Pizzagalli, DA1
Carta, MG1
Paribello, P1
Nardi, AE1
Preti, A1
Hou, YC1
Lai, CH1
Chen, J1
Gao, K1
Kemp, DE1
Komossa, K1
Depping, AM1
Gaudchau, A1
Kissling, W1
Leucht, S1
Agarwal, SM1
Rao, NP1
Venkatasubramanian, G1
Behere, RV1
Varambally, S1
Gangadhar, BN1
Montgomery, SA1
Fric, M1
Laux, G1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effects of Dopamine on Reward Processing[NCT01253421]Phase 1159 participants (Actual)Interventional2012-02-29Completed
Early Life Stress and Depression: Molecular and Functional Imaging Approaches[NCT01701258]Phase 1153 participants (Actual)Interventional2013-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Effect on Caudate Response to Cues

This statistic shows the effect (beta) that the combination of diagnosis and drug has on caudate activation after presentation of a cue. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: Scan session

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.2231
MDD-placebo-0.0391
HC-amisulpride-0.0938
HC-placebo0.0582

Effect on Caudate Response to Reward

This statistic shows the effect (beta) that the combination of diagnosis and drug has on caudate activation after Reward outcomes. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: During scan session

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.5783
MDD-placebo-0.2673
HC-amisulpride-0.33
HC-placebo0.1955

Effect on Caudate-dACC Connectivity After Reward

This statistic shows the effect (beta) that the combination of diagnosis and drug has on functional connectivity between caudate and dorsal anterior cingulate cortex (dACC) in response to reward outcomes (NCT01253421)
Timeframe: During scan session

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.3628
MDD-placebo0.3881
HC-amisulpride0.2992
HC-placebo0.6192

Effect on NAcc Response to Cues

This statistic shows the effect (beta) that the combination of diagnosis and drug has on nucleus accumbens (NAcc) activation after presentation of a cue. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: Scan session

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.2446
MDD-placebo0.0736
HC-amisulpride0.1356
HC-placebo0.2182

Effect on NAcc Response to Reward

This statistic shows the effect (beta) that the combination of diagnosis and drug has on nucleus accumbens (NAcc) activation after reward outcomes. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: During scan session

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.9377
MDD-placebo0.1578
HC-amisulpride0.4018
HC-placebo0.954

Effect on NAcc-MCC Connectivity After Reward

This statistic shows the effect (beta) that the combination of diagnosis and drug has on functional connectivity between nucleus accumbens (NAcc) and mid-cingulate cortex (MCC) in response to reward outcomes. (NCT01253421)
Timeframe: During scan session

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.4375
MDD-placebo0.324
HC-amisulpride0.4846
HC-placebo0.4877

Effect on PST Penalty Learning

This statistic shows the effect (beta) that the combination of diagnosis and drug has on the ability to learn from penalties during a Probabilistic Selection Task (PST). A higher effect size indicates greater ability to learn from penalty trials. (NCT01253421)
Timeframe: administered after scan

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.2428
MDD-placebo0.29
HC-amisulpride0.2207
HC-placebo0.2391

Effect on PST Reward Learning

This statistic shows the effect (beta) that the combination of diagnosis and drug has on the ability to learn from rewards during a Probabilistic Selection Task (PST). A higher effect size indicates greater ability to learn from reward trials. (NCT01253421)
Timeframe: administered after scan

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.6271
MDD-placebo0.7575
HC-amisulpride0.823
HC-placebo0.7545

Effect on Putamen Response to Reward

This statistic shows the effect (beta) that the combination of diagnosis and drug has on putamen activation (beta) after reward outcomes. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: During scan session

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.6338
MDD-placebo0.1709
HC-amisulpride-0.14
HC-placebo0.436

Putamen Response to Cues

This statistic shows the effect (beta) that the combination of diagnosis and drug has on putamen activation after presentation of a cue. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: Scan session

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.4969
MDD-placebo0.3955
HC-amisulpride0.4169
HC-placebo0.3808

The Effect of Diagnosis on Cortisol Reactivity

"This is a measure of area under the curve in relation to ground, a measure of total cortisol output, in response to acute stress. The acute stressor was the Maastricht Acute Stress Test (MAST). The area under the curve includes all 5 cortisol measures, with one measure before the stressor and the other four measures collected after the stressor. Given that the cortisol data were positively skewed, the cortisol measures were normalized via a log transformation prior to calculating the area under the curve.~Area under the curve with respect to ground (AUCG) is calculated AUC_g=(((cort2_log + cort1_log) * cort_t1_time) / 2)+(((cort3_log+cort2_log)*cort_t2_time)/2)+(((cort4_log+cort3_log)*cort_t3_time)/2)+(((cort5_log+cort4_log)*cort_t4_time)/2). Cort_logs are the log transformed cortisol output data (ng/ml) and the cort_times are the time spans in between each cortisol assessment." (NCT01701258)
Timeframe: 3 hour EEG Session (Session 4)

Intervention[log (ng/ml)]*min (Mean)
Control Group156.58
MDD Group186.78
CSA/RES Group152.13
CSA/MDD Group179.16

Cortisol Output in Response to a Stress Manipulation

This statistic shows the impact of the stress manipulation on the participant's salivary cortisol output. Saliva samples were collected at 5 distinct time points throughout the study session. The first saliva sample (Cort 1) was collected when the participant began the eeg session. The second (Cort 2)was taken at the end of the acute stressor. The third (Cort 3) was taken approximately fifteen minutes after the second. The fourth (Cort 4) was taken approximately ten minutes after the third. The fifth (Cort 5) was taken approximately 40 minutes after the fourth. (NCT01701258)
Timeframe: 3 hour EEG Session (Session 4)

,,,
Interventionng/ml (Mean)
Cort1Cort2Cort3Cort4Cort5
Control Group9.809.1115.5512.897.07
CSA/MDD Group14.198.6314.3114.2211.01
CSA/RES Group10.159.5110.758.997.41
MDD Group12.5312.2815.2316.3010.34

Dopamine Active Transporter Binding Potential

"Utilizing 11C-altropane during positron emission tomography (PET) scanning allows us to measure dopamine active transporter (DAT) binding potential.~Our outcome measure is Nondisplacable Binding Potential (BPND). BPND refers to the ratio at equilibrium of specifically bound radioligand to that of nondisplaceable radioligand in tissue.~*Higher BPND scores indicate greater binding potential" (NCT01701258)
Timeframe: 1 hour PET scan (Session 3)

,,,
InterventionRatio (Mean)
CaudatePutamenAccumbens
Control Group3.1913.3612.159
CSA/MDD Group3.2163.3182.149
CSA/RES Group3.1753.2412.103
MDD Group3.1613.3592.103

Effects on Major Depressive Disorder and Childhood Sexual Abuse History on Striatal Activity in Response to Neutral and Reward Cues

"This statistic shows the influence of major depressive disorder and childhood sexual abuse history on the strength of striatal activation (caudate, putamen, accumbens) in response to neutral and reward cues during the monetary incentive delay task (MID).~Striatal activation is measured using a statistic called a beta weight. A beta weight is a standardized regression coefficient. Higher beta weights mean greater striatal activation and lower beta weights mean less striatal activation. A negative beta weight would indicate a deactivation." (NCT01701258)
Timeframe: 3 hour Drug & fMRI Session (Session 2)

,,,,,,,
Interventionbeta weight (slope) (Mean)
Caudate Response to Reward CuesCaudate Response to Neutral CuesPutamen Response to Reward CuesPutamen Response to Neutral CuesAccumbens Response to Reward CuesAccumbens Response to Neutral Cues
Control-amisulpride.200.222.608.455.401.016
Control-placebo.468.185.663.518.480.120
CSA/MDD-amisulpride.514.254.550.550.692.385
CSA/MDD-placebo.054-.243.468.357.255.040
CSA/RES-amisulpride.511.050.745.493.679-.123
CSA/RES-placebo.079-.370.419.240.310-.381
MDD-amisulpride.403.047.698.384.351-.111
MDD-placebo.608.156.814.621.428.140

Effects on Major Depressive Disorder and Childhood Sexual Abuse History on Striatal Activity in Response to Neutral and Reward Feedback

"This statistic shows the influence of major depressive disorder and childhood sexual abuse history on the strength of striatal activation (caudate, putamen, accumbens) in response to neutral and reward feedback during the monetary incentive delay task (MID).~Striatal activation is measured using a statistic called a beta weight. A beta weight is a standardized regression coefficient. Higher beta weights mean greater striatal activation and lower beta weights mean less striatal activation. A negative beta weight would indicate a deactivation." (NCT01701258)
Timeframe: 3 hour Session 2 (fMRI session)

,,,,,,,
Interventionbeta weight (slope) (Mean)
Caudate Response to Reward FeedbackCaudate Response to Neutral FeedbackPutamen Response to Reward FeedbackPutamen Response to Neutral FeedbackAccumbens Response to Reward FeedbackAccumbens Response to Neutral Feedback
Control-amisulpride-.613-.793-.533-.375.074-.503
Control-placebo-.273-.105-.131.164.069.109
CSA/MDD-amisulpride-.101-.233-.018-.021-.158.010
CSA/MDD-placebo.040-.608.063-.418.839-.332
CSA/RES-amisulpride-.197-.501-.087-.142-.046-.079
CSA/RES-placebo-.905-.959-.304-.276-.713-.819
MDD-amisulpride-.819-.865-.031-.229-.554-.456
MDD-placebo-.773-.733-.357-.108-.215-.039

The Effect of Major Depressive Disorder and Childhood Abuse History on a Reward-related EEG Component (Reward Positivity Component) While Under Stress

"EEG was recorded during the probabilistic reward task (the PRT task). Participants completed the Probabilistic Reward Task (PRT) twice throughout the experiment, once before stress and once after stress. The stressor was the Maastricht Acute Stress Test (MAST). This statistic shows the effect that childhood sexual abuse (CSA) and diagnosis had on a reward-related positivity EEG component recorded during the PRT, before and after stress.~Higher reward positivity amplitudes indicate a stronger neural response to reward and lower amplitudes indicate a lower neural response to rewards." (NCT01701258)
Timeframe: 3 hour EEG Session (Session 4)

,,,
Interventionamplitude (microvolts) (Mean)
Pre MASTPost MAST
Control Group2.712.06
CSA/MDD Group4.153.90
CSA/RES Group2.162.30
MDD Group4.754.99

The Effects of CSA and Diagnosis on PRT Performance Under Acute Stress

The participant's performance on the Probabilistic Reward Task (PRT) was assessed both before and after an acute stressor. The PRT is a behavioral task that measures an individual's ability to learn from rewarding stimuli and incorporate this learning into their response style (response bias). The acute stressor was the Maastricht Acute Stress Test (MAST). The score obtained is a ratio of the number of times participants correctly choose the high reward stimuli versus the low rewarding stimuli. Response bias scores range between -1 and +1. Higher response bias scores indicate a stronger response bias toward high reward stimuli. A negative response bias indicates a stronger bias toward low reward stimuli. (NCT01701258)
Timeframe: 3 hour EEG Session (Session 4)

,,,
InterventionRatio (Response Bias Score) (Mean)
PRT Block1: Before MASTPRT Block2: Before MASTPRT Block1: After MASTPRT Block2: After MAST
Control Group0.0280.1240.1280.245
CSA/MDD Group0.1670.1680.0480.127
CSA/RES Group0.0920.1300.0790.143
MDD Group0.1170.1550.0780.128

Reviews

5 reviews available for dan 2163 and Depression, Involutional

ArticleYear
Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis.
    Psychological medicine, 2023, Volume: 53, Issue:9

    Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzothiaze

2023
Current pharmacotherapeutic approaches for dysthymic disorder and persistent depressive disorder.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:14

    Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Dysthymic Diso

2019
Second-generation antipsychotics in major depressive disorder: update and clinical perspective.
    Current opinion in psychiatry, 2011, Volume: 24, Issue:1

    Topics: Adult; Amisulpride; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depr

2011
Second-generation antipsychotics for major depressive disorder and dysthymia.
    The Cochrane database of systematic reviews, 2010, Dec-08, Issue:12

    Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive

2010
Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders.
    International clinical psychopharmacology, 2002, Volume: 17 Suppl 4

    Topics: Amisulpride; Animals; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; D

2002

Trials

2 trials available for dan 2163 and Depression, Involutional

ArticleYear
Effects of a single dose of amisulpride on functional brain changes during reward- and motivation-related processing using task-based fMRI in healthy subjects and patients with major depressive disorder - study protocol for a randomized clinical trial.
    Trials, 2023, Nov-27, Volume: 24, Issue:1

    Topics: Amisulpride; Brain; Depressive Disorder, Major; Healthy Volunteers; Humans; Magnetic Resonance Imagi

2023
Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression.
    Biological psychiatry. Cognitive neuroscience and neuroimaging, 2020, Volume: 5, Issue:2

    Topics: Adult; Amisulpride; Antidepressive Agents, Second-Generation; Depression; Depressive Disorder, Major

2020
Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression.
    Biological psychiatry. Cognitive neuroscience and neuroimaging, 2020, Volume: 5, Issue:2

    Topics: Adult; Amisulpride; Antidepressive Agents, Second-Generation; Depression; Depressive Disorder, Major

2020
Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression.
    Biological psychiatry. Cognitive neuroscience and neuroimaging, 2020, Volume: 5, Issue:2

    Topics: Adult; Amisulpride; Antidepressive Agents, Second-Generation; Depression; Depressive Disorder, Major

2020
Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression.
    Biological psychiatry. Cognitive neuroscience and neuroimaging, 2020, Volume: 5, Issue:2

    Topics: Adult; Amisulpride; Antidepressive Agents, Second-Generation; Depression; Depressive Disorder, Major

2020

Other Studies

3 other studies available for dan 2163 and Depression, Involutional

ArticleYear
Brain morphology changes in a remitted patient with late-onset, drug-naïve, non-psychotic major depressive disorder after amisulpride monotherapy.
    The Journal of neuropsychiatry and clinical neurosciences, 2013,Spring, Volume: 25, Issue:2

    Topics: Amisulpride; Antipsychotic Agents; Brain; Depressive Disorder, Major; Female; Humans; Middle Aged; S

2013
Successful treatment of atypical depression with amisulpride: a case report.
    Asian journal of psychiatry, 2012, Volume: 5, Issue:4

    Topics: Amisulpride; Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Sulpiride; Young Adu

2012
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].
    Psychiatrische Praxis, 2003, Volume: 30 Suppl 2

    Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzothiaze

2003